Opioid dependency. Mental and behavioral disorders due to use of opioids
Conditions
Interventions
Intervention 1: 32 mg buprenorphine is given as a single dose to patients and evaluate anxiety, depression, suicidal thoughts and withdrawal symptom for at least 4 days. Intervention 2: 16 mg bupreno
Treatment - Drugs
Placebo
32 mg buprenorphine is given as a single dose to patients and evaluate anxiety, depression, suicidal thoughts and withdrawal symptom for at least 4 days.
16 mg buprenorphine is given as a single dose to patients and evaluate anxiety, depression, suicidal thoughts and withdrawal symptom for at least 4 days.
Placebo is given as a single dose to patients and evaluate anxiety, depression, suicidal thoughts and withdrawal symptom for at least 4 days.
Sponsors
Vice chancellor of Shiraz University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
16 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: age between 16 to 60 y/o; informed consent; Opioid dependence Exclusion criteria:Patients unwilling to participate at beginning or during the study; use of other substances except Opioid as of the main substance
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of withdrawal symptoms in opiod dependents and find the best choice. Timepoint: before the first dose and first day to 4 days. Method of measurement: by interview based on DSM-5 and questionnaire (Craving and withdrawal questionnaire). | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of anxiety, depression in opiod dependents and find the best choice, suicidal thoughts. Timepoint: before the first dose and first day to 4 days. Method of measurement: by interview based on DSM-5 criteria and questionnaires (Ham-A, BSSI, BDI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJamshid Ahmadi M.D.
Shiraz University of Medical Sciences
Outcome results
None listed